aTyr Pharma Statistics
Total Valuation
aTyr Pharma has a market cap or net worth of $82.10 million. The enterprise value is $12.60 million.
Important Dates
The last earnings date was Thursday, March 5, 2026, after market close.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
aTyr Pharma has 98.05 million shares outstanding. The number of shares has increased by 25.21% in one year.
| Current Share Class | 98.05M |
| Shares Outstanding | 98.05M |
| Shares Change (YoY) | +25.21% |
| Shares Change (QoQ) | +0.88% |
| Owned by Insiders (%) | 2.50% |
| Owned by Institutions (%) | 55.62% |
| Float | 95.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 417.13 |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 66.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.30, with a Debt / Equity ratio of 0.18.
| Current Ratio | 5.30 |
| Quick Ratio | 5.25 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -108.11% and return on invested capital (ROIC) is -59.74%.
| Return on Equity (ROE) | -108.11% |
| Return on Assets (ROA) | -51.12% |
| Return on Invested Capital (ROIC) | -59.74% |
| Return on Capital Employed (ROCE) | -99.71% |
| Weighted Average Cost of Capital (WACC) | 6.37% |
| Revenue Per Employee | $3,167 |
| Profits Per Employee | -$1.24M |
| Employee Count | 60 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.32% in the last 52 weeks. The beta is 0.56, so aTyr Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -77.32% |
| 50-Day Moving Average | 0.86 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 44.53 |
| Average Volume (20 Days) | 1,072,639 |
Short Selling Information
The latest short interest is 18.80 million, so 19.18% of the outstanding shares have been sold short.
| Short Interest | 18.80M |
| Short Previous Month | 19.88M |
| Short % of Shares Out | 19.18% |
| Short % of Float | 19.67% |
| Short Ratio (days to cover) | 7.14 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of $190,000 and -$74.12 million in losses. Loss per share was -$0.80.
| Revenue | 190,000 |
| Gross Profit | -60.03M |
| Operating Income | -77.63M |
| Pretax Income | -74.12M |
| Net Income | -74.12M |
| EBITDA | -76.96M |
| EBIT | -77.63M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $78.69 million in cash and $12.03 million in debt, with a net cash position of $66.65 million or $0.68 per share.
| Cash & Cash Equivalents | 78.69M |
| Total Debt | 12.03M |
| Net Cash | 66.65M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 67.29M |
| Book Value Per Share | 0.69 |
| Working Capital | 65.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$61.99 million and capital expenditures -$77,000, giving a free cash flow of -$62.06 million.
| Operating Cash Flow | -61.99M |
| Capital Expenditures | -77,000 |
| Depreciation & Amortization | 664,000 |
| Net Borrowing | -539,000 |
| Free Cash Flow | -62.06M |
| FCF Per Share | -$0.63 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -40,856.32% |
| Pretax Margin | -39,012.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
aTyr Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.21% |
| Shareholder Yield | -25.21% |
| Earnings Yield | -93.52% |
| FCF Yield | -78.31% |
Analyst Forecast
The average price target for aTyr Pharma is $4.20, which is 401.58% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.20 |
| Price Target Difference | 401.58% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 351.46% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2019. It was a reverse split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
aTyr Pharma has an Altman Z-Score of -4.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.26 |
| Piotroski F-Score | 2 |
